SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, announced that data from four Phase 3 clinical trials of the company’s product candidate Silenor® (doxepin) for the treatment of insomnia were presented today at the American Psychiatric Association (APA) 2009 annual meeting in San Francisco.
